Clinical Trial Update: A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

Phase 2 trial comparing risankizumab to placebo in adults with moderate to severe hidradenitis suppurativa completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: COMPLETED | Results posted: 2022-08-11